Ipradol
Each tablet contains 0.5 mg hexoprenaline sulphate
Company Name
ADCO/Nycomed - Austria
Pharmaceutical form
Tablets
Package
20,100 tablets (each 10 tablets/strip)
Indications
Treatment and prevention of dyspnoea due to bronchial asthma, spasmodic bronchitis, chronic bronchitis and emphysema.
Warning & Precautions
If contra-indications apply or side effects occur, please inform your doctor . Diabetics taking IPRADOL® should check blood-sugar levels in regular intervals. Please inform your dpcotr if you get pregnant during treatment.
Product Type
Human
Dosage
Unless otherwise prescribed by your doctor, strictly observe dosage recommendations. Adults: 1 or a maximum of 2 tablets three times a day or 1 tablet every 4 hours, respectively. Children 3-6 months : 1/4 of a tablet :1-2 times a day 6-12 months :1/4 of a tablet :1-3 times a day 1-3 years 1/4 to 1/2 a tablet : 1 -3 times a day 3 - 6 years 1/2 of a table : 1 - 3 times a day 6 - 10 years 1 of a tablet : 1 - 3 times a day Tablets should be taken half an hour before meals with a small amount of liquid
Adverse Reactions
During treatment (especially if high doses are administered), restlessness, dizziness, slight trembling of the fingers, sweating, palpitations, increase in pulse rate (above 100 beats per minute) and cardialgias may occur. In rare cases sickness, nausea and vomiting may occur.
Contra Indications
1PRADOL® must not be administered in case of: certain forms of heart diseases, recent cardiac infarction, severe hypertension, severe kidney or liver disease, hyperthyroidism, glaucoma
Drug Interactions
IPRADOL® may interact with several drugs: Certain drugs against high blood pressure (e.g. B-receptor blockers) decrease the effect of IPRADOL® or completely neutralize it. The action of antidiabetic drugs is reduced. Certain circulatory and asthma drugs (sympathomimetic drugs) specifically accentuate the side effects of IPRADOL® (e.g. palpitations, increased pulse rate). IPRADOL® should not be administered together with ergot alkaloids, simultaneous administration of certain narcotics (e.g. halothane) entails the risk of cardiac irregularities. IPRADOL® must not be administered during pregnancy together with drugs containing vitamin D, calcium and dihydrotachysterol). Please inform your doctor of all medication you are currently taking, especially if it was prescribed by another specialist.
Ipradol AmpouleEach ampoule of 2 mi contains Hexoprenaline sulphate 0.00525mg / 2ml
Company Name
ADCO/Nycomed - Austria
Pharmaceutical form
l.v. injection or i.v. infusion
Package
5 x 2 ml, 5 x 5 x 2 ml (multi-pack)
Indications
Imminent or acute attack of bronchial asthma, bronchitis (especially with spastic component), chronic bronchitis due to pulmonary emphysema, bronchial spasms of various origins.
Warning & Precautions
When administering IPRADOL to diabetics, frequently check blood sugar levels
Product Type
human
Dosage
For maximum therapeutic effect, determine individually most effective dose Adults: For acute asthma attacks, inject 1 ampoule, in case of severe dyspnoea inject 1 1/2 to a maximum of 2 ampoules. In case of status asthmaticus, administer 1 ampouie 3 to 4 times over a period of 24 hours. Children: 1 - 3 times daily 3 - 6 months 1 ug 6-12 months 2 ug 1 - 3 years 2 - 3 jug 3- 10 years 3 - 4 ug The ampoule should be injected slowly i.v. (2 minutes per ampoule). It is possible to dilute the ampoule with blood-isotonic sodium chloride or glucose solution
Adverse Reactions
IPRADOL is generally well tolerated. During treatment, restlessness, dizziness, tremor, sweating, palpitation and increase in pulse rate may occur. In rare cases, sickness, nausea or vomiting may occur. Drug contains sulphite. Certain individuals, especially asthma patients, may show hypersensitivity reactions to this component marked by: nausea, diarrhea, laboured breathing, acute asthma attack, disturbances of consciousness or shock.
Contra Indications
Hypersensitivity to one of the components of IPRADOL. Due to the sulphite contents, IPRADOL ampoules must not be administered to asthma patients suffering from hypersensitivity to sulphite. Hyperthyroidism, heart diseases, especially tachycardiac irregularities, myocarditis, mitral valve defects and idiopathic hypertrophic subvaivular aortic stenosis, severe liver or kidney disease, narrow angle glaucoma. In case of permanent hypertension and recent rnyocardial infarction, special caution has to be taken when administering IPRADOL.
Drug Interactions
Non-selective B-receptor blockers decrease or completely neutralize IPRADOL's action. Methylxanthines like theophylline intensify IPRADOL's effect. The increased storage of glycogen in the liver under glucocorticoids is decreased due to IPRADOL's glycogenolytic action. The hypoglycaemic effect of oral antidiabetics is decreased by IPRADOL. The simultaneous use of other sympathomimetic drugs, e.g. certain circulatory and asthma medications, is not recommended since it might lead to increased effects on the heart and to symptoms of overdose. IPRADOL must not be administered during pregnancy in combination with drugs containing calcium or vitamin D, as well as dihydrotachysterol or mineral corticoids. A sensitization of the heart to sympathomimetics through administration of certain narcotics (e.g. halothane) is possible. Simultaneous administration may cause cardiac irregularities
No comments:
Post a Comment